HOUSTON--(BUSINESS WIRE)--Edgeline Holdings, Inc. (OTCBB:ELHI) announced today that it now expects to close on its acquisition of Intertech Bio by the end of the month. Intertech Bio will initially focus on developing novel cancer treatments specifically targeting the brain, pancreatic and ovarian tumors. The market for cancer therapies is greater than $8 billion and will continue to increase as the population ages. The forecasted sales for cancer related therapies are $25.2 billion by 2015.
